Forvia

FRVIA

Equity

ISIN FR0000121147 / Valor 487591

Euronext - Euronext Paris (2025-11-21)

EUR 10.27+1.63%

Forvia
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Forvia is a company that specializes in the production and distribution of high-quality nutritional supplements for individuals with specific dietary needs, such as those with food allergies or sensitivities.

Summarized from source with an LLMView SourceSector: Consumer Cyclicals

Sales Performance

Sales for H1 2025 slightly decreased by 0.4% to €13,477 million compared to H1 2024, with an organic growth of 1.1% driven by the Electronics and Seating segments.

Operating Margin Improvement

The operating margin increased by 20 basis points to 5.4% of sales, up from 5.2% in H1 2024. This improvement was supported by strict cost control, effective management of US tariffs, and the early benefits of the EU-FORWARD program.

Net Cash Flow Surge

Net cash flow more than doubled to €418 million in H1 2025 from €201 million in H1 2024. This surge was driven by a €127 million increase in EBITDA and reductions in capital expenditures and capitalized R&D by €232 million.

Organizational Transformation

Forvia is advancing its organizational transformation by adopting a division-centric structure with clear P&L responsibilities. The Simplify project was launched to streamline operations and achieve a €110 million cost base reduction by 2028, supported by approximately €150 million in restructuring costs from 2025 to 2028.

Guidance Confirmation

The company reaffirmed its full-year 2025 outlook, maintaining targets for sales, operating margin, net cash flow, and leverage. This confirmation comes despite a challenging and volatile market environment, underscoring Forvia's commitment to debt reduction and strategic transformation.

Summarized from source with an LLMView Source

Key figures

34.0%1Y

-34.3%3Y

-71.3%5Y

Performance

63.3%1Y

54.9%3Y

54.4%5Y

Volatility